Human Rhinovirus (HRV)
Rhinovirus causes the most common viral infection in humans, and it has been shown to be the reason for serious exacerbations of symptoms in vulnerable patients with Chronic Obstructive Pulmonary Disease (COPD), asthma or cystic fibrosis. A rhinovirus infection can also be life-threatening in premature babies at risk. There are no approved vaccines or therapeutic products on the market against rhinovirus anywhere in the world. Hence there is dire need to develop an effective vaccine.
Despite this urgent need, Viravaxx is currently one of very few companies worldwide to focus on developing and commercializing a rhinovirus vaccine. With VVX003, Viravaxx aims at developing a vaccine with broad strain coverage as HRV shows very high variability with >200 strains and serotypes. To this end, the important HRV coat proteins VP1 and VP2 have been dissected into a library of overlapping peptides. Fusion proteins based on PCFiT have been constructed with these peptides and have demonstrated blocking activity in cell culture assays for multiple phylogenetically distant HRV strains.
After completion of preclinical development VVX003 will soon be tested in patients in a human rhinovirus challenge model.